Idorsia Ltd – SIX:IDIA.SW

Idorsia Ltd stock price today

CHF 18.87
+18.06
+2236.84%
Financial Health
0
1
2
3
4
5
6
7
8
9

Idorsia Ltd stock price monthly change

-63.77%
month

Idorsia Ltd stock price quarterly change

-63.77%
quarter

Idorsia Ltd stock price yearly change

-63.93%
year

Idorsia Ltd key metrics

Market Cap
 133.58M
Enterprise value
 2.78B
P/E
 -2.02
EV/Sales
 28.66
EV/EBITDA
 -3.55
Price/Sales
 17.59
Price/Book
 -2.58
PEG ratio
 0.08
EPS
 -0.25
Revenue
 141.41M
EBITDA
 -146.66M
Income
 -55.87M
Revenue Q/Q
 -52.16%
Revenue Y/Y
 25.21%
Profit margin
 -852.6%
Oper. margin
 -826.93%
Gross margin
 71.91%
EBIT margin
 -826.93%
EBITDA margin
 -103.71%

Get more financial ratios!

  • Every financial ratio you might need

  • 10 years history

  • Forward ratios (Analysts estimates)

Sign up &
create your own Smart Feed

Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.

Sign up for free

Idorsia Ltd stock price history

Idorsia Ltd stock forecast

Idorsia Ltd financial statements

Profit Margin

Idorsia Ltd (SIX:IDIA.SW): Profit margin
Jun 2023 29.93M -193.11M -645.21%
Sep 2023 79.91M 224.04M 280.35%
Dec 2023 21.51M -116.67M -542.33%
Mar 2024 10.05M 29.86M 296.88%
IDIA.SW income statement history

Idorsia Ltd Financials Estimate

Idorsia Ltd (SIX:IDIA.SW): Analyst Estimates
2025 206.48M -355.81M -172.32%
2026 402.02M -153.91M -38.29%
2027 390M -103.38M -26.51%
2028 479M -48.12M -10.05%

  • Analysts Price target

  • Financials & Ratios estimates

Show more

Quarterly Earnings

Idorsia Ltd (SIX:IDIA.SW): Earnings per share (EPS)
2023-04-25 -1.31971 -1.19
IDIA.SW earnings history

Debt to Assets

Idorsia Ltd (SIX:IDIA.SW): Debt to assets
Jun 2023 527763000 1.56B 297.24%
Sep 2023 653120000 1.48B 227.24%
Dec 2023 499996000 1.46B 293.75%
Mar 2024 780585000 1.71B 219.99%
IDIA.SW balance sheet history

Cash Flow

Idorsia Ltd (SIX:IDIA.SW): Cash Flow
Jun 2023 -192.03M -3.03M 29.88M
Sep 2023 -76.22M 266.99M -30M
Dec 2023 -110.99M 52.24M 0
Mar 2024 -118.30M 307.28M 0
IDIA.SW cash flow history

Idorsia Ltd alternative data

Idorsia Ltd
Employees

Idorsia Ltd (SIX:IDIA.SW): Employee count
Aug 2023 636
Sep 2023 636
Oct 2023 636
Nov 2023 636
Dec 2023 636
Jan 2024 636
Feb 2024 636
Mar 2024 636
Apr 2024 636
May 2024 636
Jun 2024 636
Jul 2024 636

Idorsia Ltd other data

Frequently Asked Questions (FAQ)

  • What's the price of Idorsia Ltd stock today?

    One share of Idorsia Ltd stock can currently be purchased for approximately $18.87.

  • When is Idorsia Ltd's next earnings date?

    Unfortunately, Idorsia Ltd's (IDIA.SW) next earnings date is currently unknown.

  • Does Idorsia Ltd pay dividends?

    No, Idorsia Ltd does not pay dividends.

  • How much money does Idorsia Ltd make?

    Idorsia Ltd has a market capitalization of 133.58M and it's past years’ income statements indicate that its last revenue has increased compared to the previous period by 56.93% to 152.39M US dollars. Idorsia Ltd made a loss 297.92M US dollars in net income (profit) last year or -$1.19 on an earnings per share basis.

  • What is Idorsia Ltd's stock symbol?

    Idorsia Ltd is traded on the SIX under the ticker symbol "IDIA.SW".

  • What is Idorsia Ltd's primary industry?

    Company operates in the Healthcare sector and Biotechnology industry.

  • How do i buy shares of Idorsia Ltd?

    Shares of Idorsia Ltd can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

  • How many employees does Idorsia Ltd have?

    As Jul 2024, Idorsia Ltd employs 636 workers.

  • When Idorsia Ltd went public?

    Idorsia Ltd is publicly traded company for more then 8 years since IPO on 16 Jun 2017.

  • What is Idorsia Ltd's official website?

    The official website for Idorsia Ltd is idorsia.com.

  • How can i contact Idorsia Ltd?

    Idorsia Ltd can be reached via phone at +41 58 844 10 10.

Idorsia Ltd company profile:

Idorsia Ltd

idorsia.com
Exchange:

SIX

Full time employees:

636

Industry:

Biotechnology

Sector:

Healthcare

Idorsia Ltd, a biopharmaceutical company, discovers, develops, and commercializes drugs for unmet medical needs in Switzerland. The company has a clinical development pipeline that cover various therapeutic areas, including CNS, cardiovascular, and immunological disorders, as well as orphan diseases. Idorsia Ltd has a collaboration agreement with Janssen Biotech Inc. to jointly develop and commercialize aprocitentan and its derivative compounds or products; license agreement with Mochida Pharmaceutical for the supply, co-development, and comarketing of daridorexant; and Hoffman-La Roche Inc. to develop and market compounds in the field of cancer immunotherapy. It also has a collaboration with Antares Pharma, Inc. for the development of a self- administered drug device product for Selatogrel; and Neurocrine Biosciences, Inc. to develop and commercialize ACT-709478, which is in Phase II clinical trial for the treatment of epilepsy. The company was incorporated in 2017 and is headquartered in Allschwil, Switzerland.

+41 58 844 10 10
Hegenheimermattweg 91
Allschwil, 4123

:
ISIN: CH0363463438
CUSIP: H3879B109